Arizona is bringing back its iconic 'cactus' logo to the McKale Center floor, and asking fans exactly how to do so. The school produced four images of what the court could look like, all of which ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

PARIS — France's Sanofi has agreed to buy US-based Blueprint Medicines Corp. for over $9 billion to boost its position in rare immunology diseases, in what would be the biggest health care deal in ...

Sanofi has agreed to acquire US-based Blueprint Medicines for up to US$9.5bn, marking one of the largest European pharmaceutical deals of the year and a significant expansion of its rare disease and ...

Sanofi SA will buy Blueprint Medicines Corp. for $9.1 billion equity value, in a deal that sees the European pharmaceutical firm expand its rare immunological disease portfolio. Sanofi will pay $ ...

Sanofi has entered into an agreement to acquire Blueprint Medicines Corp., a U.S.-based biopharma company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven ...

Paris — France’s Sanofi has agreed to buy US-based Blueprint Medicines Corporation for up to $9.5bn to boost its position in rare immunology diseases, in the biggest deal struck by a European ...

Paris and Cambridge, MA. June 2, 2025. Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare ...

Sanofi SAN-1.06%decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC 0.09%increase; green up pointing triangle for up to $9.5 billion, the French drugmaker’s biggest move ...